US FDA: Quality Considerations for Continuous Manufacturing; Draft Guidance for Industry
Read more…
US FDA: Product-Specific Guidance’s for Generic Drug Development
Read more…
UK Seeks to Increase Clinical Trials Transparency
Read more…
TGA Seeks Feedback on Criteria to Support Drug Down-Scheduling
Read more…
Assessing the Effects of Food on Drugs in INDs and NDAs — Clinical Pharmacology Considerations -Draft Guidance
Read more…
Bioavailability Studies Submitted in NDAs or INDs — General Considerations – Draft Guidance
Read more…
FDA Defends its Efforts to Ensure Generic Drug Quality
Read more…
Govt amends D&C Rules to regulate brand names; cos needs to furnish undertaking to avoid confusion over LASA drugs
Read more…
TN DCA to introduce digital services for accepting applications & issuing licenses for pharma manufacturers
Read more…
Cosmetics licences may come with product composition details to enhance safety; new clause proposed in Cosmetics Rules 2018
Read more…
Govt brings 42 non-scheduled cancer drugs under price control, trade margin capped at 30 per cent
Read more…
Procedural update on submission of Type I variations to EMA in March, April and May 2019
Read more…
EMA Kicks Off Series of EU MDR/IVDR Guidance
Read more…
US FDA: Office of Pharmaceutical Quality – 2018 Annual report
Read more…
DCGI enlists procedures for regularisation of 83 FDCs, issues 7 pointers to be adhered for approval submission before June
Read more…
India’s bid to bring OTC drug regulations gains momentum; 3-member panel in place to examine expert recommendations
Read more…
Change of time zone due to EMA’s relocation in March 2019
Read more…
HPRA- Guide to Reclassification (Switching) of Legal Supply Status for Human Medicinal Products
Read more…
TGA Proposes 5 Medical Device Classifications in Line with EU MDR
Read more…
CDRH Classifies Software App for Contraception into Class II
Read more…
CDRH Seeks to Exempt Certain Flow Cytometers from 510(k) Reviews
Read more…
CDER Guidance Agenda for 2019: What’s Coming
Read more…
MHRA Sets No-Deal Brexit Process for Pharma Submissions
Read more…
New Impurity Found in Blood Pressure Drug Prompts Expanded FDA Recall
Read more…
EMA- Regulatory information – adjusted fees for applications to EMA from 1 April 2019
Read more…
Transition to ISO 13485:2016 Comes to an End
Read more…
FDA Finalizes Guidance on 503B Bulks List
Read more…
CDSCO comes out with clarification about issuance of NOC for Form 29 license
http://www.pharmabiz.com/NewsDetails.aspx?aid=114430&sid=1
Like this:
Like Loading...
Posted by 